Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 2, 2014, Pages 226-231

  Kose, Eiji ^a   An, Taesong ^b   Kikkawa, Akihiko ^b   Matsumoto, Yoshiaki ^a   Hayashi, Hiroyuki ^a  

^a NIHON UNIVERSITY   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

Atorvastatin; Chronic kidney disease (CKD) stages 3; Hyperlipidemia; Hyperuricemia; Rosuvastatin

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SULFONAMIDES; URIC ACID;

EID: 84893223617     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00418     Document Type: Article

References (23)

1. Hisatome I. Impact of serum uric acid level on the cardiovascular system as a risk factor. Folia Pharmacologica Japonica, 136, 325-329 (2010).
2. Ichida K. Hyperuricemia and metabolic syndrome. Folia Pharmacologica Japonica, 136, 321-324 (2010).
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol., 16, 529-538 (2005).
4. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis., 41, 565-570 (2003).
5. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am. Heart J., 148, 635-640 (2004).
6. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J. Cardiovasc. Pharmacol. Ther., 18, 13-18 (2013).
7. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann. Rheum. Dis., 66, 1056-1058 (2007).
8. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J. Clin. Rheumatol., 12, 61-65 (2006).
9. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol., 42, 333-335 (1992).
10. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int., 49, 1787-1790 (1996).
11. Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, Hosoya T. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern. Med., 49, 89-94 (2010).
12. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis., 45, 485-493 (2005).
13. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 366, 1849-1861 (2005).
14. Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J. Pharmacol. Exp. Ther., 276, 125-129 (1996).
15. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J. Hypertens., 19, 1855-1860 (2001).
16. Rigatto C, Levin A, House AA, Barrett B, Carlisle E, Fine A. Atheroma progression in chronic kidney disease. Clin. J. Am. Soc. Nephrol., 4, 291-298 (2009).
17. Miyagi M, Ishii H, Murakami R, Isobe S, Hayashi M, Amano T, Arai K, Yoshikawa D, Ohashi T, Uetani T, Yasuda Y, Matsuo S, Matsubara T, Murohara T. Impact of renal function on coronary plaque composition. Nephrol. Dial. Transplant., 25, 175-181 (2010).
18. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta - analysis. J. Am. Soc. Nephrol., 17, 2006-2016 (2006).
19. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin. J. Am. Soc. Nephrol., 2, 1131-1139 (2007).
20. Clinical Trials. gov, Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease (PLANET 1): 〈http://clinicaltrials.gov/ct2/show/NCT00296374?term=PLANET+l&rank= 1〉, cited May 17, 2013.
21. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP, GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis., 43, 589-599 (2004).
22. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 17, 1527-1531 (1997).
23. Nezami N, Safa J, Salari B, Ghorashi S, Khosraviani K, Davari-Farid S, Hashemi-Aghdam Y, Nargabad ON, Tabrizi JS. Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. Nucleosides Nucleotides Nucleic Acids, 31, 353-363 (2012).